Year-End Cheer For Glenmark As Ryaltris To Debut In Australia
Executive Summary
Glenmark is ending 2019 on a buoyant note, with its rhinitis therapy getting the go-ahead in Australia. Though not seen as a huge commercial opportunity in the island continent, the clearance augurs well for the product’s overall trajectory.
You may also be interested in...
Deal Watch: Vir Partnering With Alnylam, WuXi On Coronavirus Treatments
US biotech expands 2017 collaboration with Alnylam and inks collaboration with WuXi. Plus deals involving AbbVie, Allergan, Amazon, Thermo Fisher, Qiagen, Boehringer Ingelheim, Trutino, Taiho, Arcus, Eisai, Fuji Yakuhin, Hikma, Glenmark, Hanmi, GC, Bayer, GW.
Monroe Site Commercialization ‘Critical’ For Glenmark’s US Step-Up
Glenmark expects its first US manufacturing site to go commercial next year, accelerating growth in that market, while it sets right certain compliance blips back home. The Indian firm is also on course to divest certain non-core assets but notes that bringing in a minority partner for its API unit is not a priority.
FDA Warns Glenmark Over Temperature Excursions, Gritty Topicals
Firm should have addressed complaints of gritty topicals and compromised container/closures, and its own findings about overheated creams, the US FDA says.